189 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
Potential for 1st oral therapeutic to disrupt injectable market for GHD Regulatory Path Clarity
Supplementary Materials
32 rhGH Market Gross Sales
DEFA14A
LUMO
Lumos Pharma Inc
12 Apr 24
Additional proxy soliciting materials
5:27pm
Definitive Additional Materials
☐ Soliciting Material Pursuant to § 240.14a-12
LUMOS PHARMA, INC.
(Name of Registrant as Specified In Its Charter … :
5.Total fee paid:
☐ Fee paid previously with preliminary materials.
☐ Check box if any part of the fee is offset as provided by Exchange Act Rule
8-K
EX-99.1
w4j1ej j36mx31x70
15 Nov 23
Other Events
4:38pm
8-K
EX-99.2
3m5hi2cf 4g
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.2
uvbneq5aughn0 vhvg
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
u6ifbti4
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
nle m8ev88z8awkc
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
0jj651tb ge3
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
DEFA14A
mou14yegi 6m8q6p
31 Mar 23
Additional proxy soliciting materials
4:43pm
8-K
EX-99.2
zog1 wyawn
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.2
70ejo2sjaod k9eyjkf
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
424B5
wbfkqep
29 Aug 22
Prospectus supplement for primary offering
5:14pm